The Chemoprevention Branch of the Division of Cancer Prevention and Control at the National Center Institute directs a program to identify and develop drugs for human use that will prevent, delay, or reverse the progression of cellular dysplasia (e.g. intraepithelial neoplasia) to invasive cancer. Part of the drug research and development process involves preclinical toxicology studies. These studies are performed under Good Laboratory Practices according to guidance documents published by the Food and Drug Administration and are used to support Investigational New Drug application and eventually New Drug Applications to the FDA for the marketing approval of cancer chemopreventive agents. The contractor shall complete four (4) developmental, teratology Segment II evaluations in both rats and rabbits within 2 years of contract award. The compound to e evaluated will be specified by the NCI. A range finding and a definitive test shall be conducted for each species. Evaluation shall include material and fetal toxicities and visceral and skeletal fetal malformations.

Agency
National Institute of Health (NIH)
Institute
Division of Cancer Prevention And Control (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CN075126-001
Application #
6153041
Study Section
Project Start
1997-09-30
Project End
Budget Start
1999-09-14
Budget End
2000-03-31
Support Year
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Illinois at Chicago
Department
Type
Other Domestic Higher Education
DUNS #
121911077
City
Chicago
State
IL
Country
United States
Zip Code
60612